· 个股论点
$HIMS 隔夜交易即将开始，周五收盘价为 $22。 此前该股交易价为 $70，但鉴于： - $NVO / 美国政府诉讼威胁使公司破产 - $HIMS 来自 GLP-1 的收入减速。 空头做空了该公司 40% 以上的流通盘。 所有这一切在周五盘后发生了逆转，据彭博社报道，$NVO 与 $HIMS 达成合作，这是一个极其令人惊讶的事件。 由于收入重新加速、为全球扩张进行的新收购、资产负债表无破产威胁，以及现在与 $NVO 的合作： 空头现在面临无限亏损，做空了接近一半的流通盘。 目前的格局看起来非常适合发生逼空(short squeeze)。 然而，结果主要取决于散户的反应，或者他们是否会向空头投降。 无论如何，每个人都会关注周一，看看 $HIMS 的仙人掌药丸(cactus pills)是否能作为对抗原油的宏观经济避险资产。
$HIMS overnight trading will begin soon after finishing Friday at $22. Previously it traded at $70, but given: - $NVO / US Gov lawsuit threatening to bankrupt the company - $HIMS revenue deceleration from GLP-1. Short sellers shorted 40%+ of the company’s float. All of that flipped Friday after hours once $NVO partnered up with $HIMS per Bloomberg, in an extremely surprising event. Due to revenue reaccelerating, new acquisitions for global expansion, no threats of balance sheet insolvency, and now a partnership with $NVO: Short sellers now face infinite losses, selling close to half of the float short. And the setup looks prime for a short squeeze. However, the outcome primarily depends on how retail reacts or if they capitulate to short sellers. Either way, everyone will be watching Monday to see whether $HIMS cactus pills serves as a macroeconomic flight to safety against crude oil.